𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A comparative study of physical performance measures in Parkinson's disease

✍ Scribed by Haruko Tanji; Ann L. Gruber-Baldini; Karen E. Anderson; Ingrid Pretzer-Aboff; Stephen G. Reich; Paul S. Fishman; William J. Weiner; Lisa M. Shulman


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
223 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The objective of this study is to compare physical performance measures for their ability to discriminate between levels of disability and disease severity in Parkinson's disease (PD). Disability in PD is commonly assessed by patient self‐report, which may be limited by patient insight. Methods: Seventy‐nine patients with PD were tested with seven performance measures: Physical Performance Test (PPT), modified Physical Performance Test (mPPT), Short Physical Performance Battery (SPPB), Performance Test of Activities of Daily Living (PADL), Berg Balance Scale (BBS), Timed Up and Go (TUG), and Functional Reach (FR). These measures were compared with patient‐reported disability on the Older Americans Resource and Services Disability subscale (OARS) and disease severity on the Unified Parkinson's Disease Rating Scale (UPDRS). The performance measures were more sensitive to levels of disease severity than disability. Four measures discriminated across quartiles of disability (PPT, mPPT, BBS, TUG: P < 0.05), whereas all seven measures discriminated across quartiles of the Total UPDRS (PPT, mPPT, BBS, TUG, FR: P < 0.01; SPPB, PADL: P < 0.05). However, no measure consistently discriminated between subgroups with a range of early and advanced disease severity. The seven physical performance measures showed different profiles of strengths and weaknesses in assessing disability and disease severity. The results of this study will facilitate choosing performance measures for clinical care and clinical trials in PD. © 2008 Movement Disorder Society


📜 SIMILAR VOLUMES


Clinical measures of progression in Park
✍ Werner Poewe 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract Despite all recent advances in symptomatic therapy Parkinson's disease (PD) continues to be a relentlessly progressive neurodegenerative disorder. Therefore therapies that will slow or hold disease progression are a major medical unmet need in PD. Clinical measures of disease progressio

“Pure” striatonigral degeneration and Pa
✍ Dr. Neziha Gouider-Khouja; Marie Vidailhet; Anne-Marie Bonnet; Jacques Pichon; Y 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 636 KB

Striatonigral degeneration (SND) is difficult to diagnose in vivo. The purpose of this study was to detect the best indicators for an early and reliable diagnosis of the disease. Eighteen patients clinically diagnosed as having SND were selected with rigorous inclusion criteria and compared to 18 pa

Comparing exercise in Parkinson's diseas
✍ Georg Ebersbach; Almut Ebersbach; Daniela Edler; Olaf Kaufhold; Matthias Kusch; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

## Abstract Physiotherapy is widely used in Parkinson's disease (PD), but there are few controlled studies comparing active interventions. Recently, a technique named “LSVT®BIG” has been introduced. LSVT®BIG is derived from the Lee Silverman Voice Treatment and focuses on intensive exercising of hi

A comparative study of odor identificati
✍ Sanne Boesveldt; Dagmar Verbaan; Dirk L. Knol; Martine Visser; Stephanie M. van 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

## Abstract The aim of this study was to compare the characteristics of odor discrimination and odor identification deficits in a large population of patients with Parkinson's disease (PD) and to determine which of these olfactory tests best distinguishes between patients with PD and control subjec

Measurement of rigidity in Parkinson's d
✍ Dr. Arthur Prochazka; David J. Bennett; Marilee J. Stephens; Susan K. Patrick; R 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 914 KB

## Abstract Clinical assessment of rigidity in parkinsonian patients is largely qualitative. The reliability and validity of the assessments are sometimes in doubt. Several “engineering” methods of quantifying rigidity have been described, but none has been adopted into general clinical practice. A

Pergolide compared with bromocriptine in
✍ Dr. G. Pezzoli; E. Martignoni; C. Pacchetti; V. A. Angeleri; P. Lamberti; A. Mur 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 511 KB

## Abstract We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single‐blind, crossover study. Patients were placed randomly on the sequence bromocriptine‐pergolide (12 + 12 weeks) or vice